85 related articles for article (PubMed ID: 24105694)
1. Tolerability and efficacy of pegylated interferon-α-2a in combination with imatinib for patients with chronic-phase chronic myeloid leukemia.
Johnson-Ansah H; Guilhot J; Rousselot P; Rea D; Legros L; Rigal-Huguet F; Nicolini FE; Mahon FX; Preudhomme C; Guilhot F
Cancer; 2013 Dec; 119(24):4284-9. PubMed ID: 24105694
[TBL] [Abstract][Full Text] [Related]
2. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.
Preudhomme C; Guilhot J; Nicolini FE; Guerci-Bresler A; Rigal-Huguet F; Maloisel F; Coiteux V; Gardembas M; Berthou C; Vekhoff A; Rea D; Jourdan E; Allard C; Delmer A; Rousselot P; Legros L; Berger M; Corm S; Etienne G; Roche-Lestienne C; Eclache V; Mahon FX; Guilhot F; ;
N Engl J Med; 2010 Dec; 363(26):2511-21. PubMed ID: 21175313
[TBL] [Abstract][Full Text] [Related]
3. Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia.
Simonsson B; Gedde-Dahl T; Markevärn B; Remes K; Stentoft J; Almqvist A; Björeman M; Flogegård M; Koskenvesa P; Lindblom A; Malm C; Mustjoki S; Myhr-Eriksson K; Ohm L; Räsänen A; Sinisalo M; Själander A; Strömberg U; Bjerrum OW; Ehrencrona H; Gruber F; Kairisto V; Olsson K; Sandin F; Nagler A; Nielsen JL; Hjorth-Hansen H; Porkka K;
Blood; 2011 Sep; 118(12):3228-35. PubMed ID: 21685374
[TBL] [Abstract][Full Text] [Related]
4. Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating factor.
Cortes J; Quintás-Cardama A; Jones D; Ravandi F; Garcia-Manero G; Verstovsek S; Koller C; Hiteshew J; Shan J; O'Brien S; Kantarjian H
Cancer; 2011 Feb; 117(3):572-80. PubMed ID: 20886606
[TBL] [Abstract][Full Text] [Related]
5. [Imatinib combination therapies--the new CML Study 4].
Helmann R; Berger U; Engelich G
Dtsch Med Wochenschr; 2002 Oct; 127(42):224-6. PubMed ID: 12430568
[No Abstract] [Full Text] [Related]
6. [Molecular response with triple therapy in patients with chronic myeloid leukemia].
López-Arroyo JL; Rico-Ramos HJ; Portillo-García ML
Rev Med Inst Mex Seguro Soc; 2014; 52(3):262-5. PubMed ID: 24878083
[TBL] [Abstract][Full Text] [Related]
7. [Imatinib-New, molecular therapeutic possibility in chronic myeloid leukemia. The IRIS Study].
Berger U; Hehlmann R
Internist (Berl); 2004 Jan; 45(1):102-3. PubMed ID: 14735248
[No Abstract] [Full Text] [Related]
8. Pegylated IFN-α2a combined to imatinib mesylate 600mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600mg daily alone.
Nicolini FE; Hayette S; Legros L; Rousselot P; Maloisel F; Tulliez M; Guerci A; Charbonnier A; Prébet T; Rigal-Huguet F; Chabane K; Magaud JP; Paillet C; Pivot C; Michallet M
Leuk Res; 2011 Jan; 35(1):80-6. PubMed ID: 20605207
[TBL] [Abstract][Full Text] [Related]
9. Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib.
Cortes J; Jabbour E; Daley GQ; O'Brien S; Verstovsek S; Ferrajoli A; Koller C; Zhu Y; Statkevich P; Kantarjian H
Cancer; 2007 Sep; 110(6):1295-302. PubMed ID: 17623836
[TBL] [Abstract][Full Text] [Related]
10. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.
O'Brien SG; Guilhot F; Larson RA; Gathmann I; Baccarani M; Cervantes F; Cornelissen JJ; Fischer T; Hochhaus A; Hughes T; Lechner K; Nielsen JL; Rousselot P; Reiffers J; Saglio G; Shepherd J; Simonsson B; Gratwohl A; Goldman JM; Kantarjian H; Taylor K; Verhoef G; Bolton AE; Capdeville R; Druker BJ;
N Engl J Med; 2003 Mar; 348(11):994-1004. PubMed ID: 12637609
[TBL] [Abstract][Full Text] [Related]
11. Imatinib and pegylated IFN-α2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response.
Koskenvesa P; Kreutzman A; Rohon P; Pihlman M; Vakkila E; Räsänen A; Vapaatalo M; Remes K; Lundán T; Hjorth-Hansen H; Vakkila J; Simonsson B; Mustjoki S; Porkka K
Eur J Haematol; 2014; 92(5):413-20. PubMed ID: 24372965
[TBL] [Abstract][Full Text] [Related]
12. Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure.
Cortes J; Quintás-Cardama A; Garcia-Manero G; O'Brien S; Jones D; Faderl S; Ebarb T; Giles F; Thomas D; Kantarjian H
Cancer; 2007 Nov; 110(9):2000-6. PubMed ID: 17849425
[TBL] [Abstract][Full Text] [Related]
13. High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group.
Thielen N; van der Holt B; Verhoef GE; Ammerlaan RA; Sonneveld P; Janssen JJ; Deenik W; Falkenburg JH; Kersten MJ; Sinnige HA; Schipperus M; Schattenberg A; van Marwijk Kooy R; Smit WM; Chu IW; Valk PJ; Ossenkoppele GJ; Cornelissen JJ
Ann Hematol; 2013 Aug; 92(8):1049-56. PubMed ID: 23572137
[TBL] [Abstract][Full Text] [Related]
14. Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia.
Talpaz M; Rakhit A; Rittweger K; O'Brien S; Cortes J; Fettner S; Hooftman L; Kantarjian H
Clin Cancer Res; 2005 Sep; 11(17):6247-55. PubMed ID: 16144928
[TBL] [Abstract][Full Text] [Related]
15. Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia.
Burchert A; Müller MC; Kostrewa P; Erben P; Bostel T; Liebler S; Hehlmann R; Neubauer A; Hochhaus A
J Clin Oncol; 2010 Mar; 28(8):1429-35. PubMed ID: 20142590
[TBL] [Abstract][Full Text] [Related]
16. A phase 1 study to evaluate the feasibility and efficacy of the addition of ropeginterferon alpha-2b to imatinib treatment in patients with chronic phase chronic myeloid leukemia (CML) not achieving a deep molecular response (molecular remission 4.5)-AGMT_CML 1.
Heibl S; Buxhofer-Ausch V; Schmidt S; Webersinke G; Lion T; Piringer G; Kuehr T; Wolf D; Melchardt T; Greil R; Thaler J
Hematol Oncol; 2020 Dec; 38(5):792-798. PubMed ID: 32757230
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near-complete cytogenetic response to interferon-alpha.
Branford S; Hughes T; Milner A; Koelmeyer R; Schwarer A; Arthur C; Filshie R; Moreton S; Lynch K; Taylor K
Cancer; 2007 Aug; 110(4):801-8. PubMed ID: 17607681
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial.
Guilhot F; Rigal-Huguet F; Guilhot J; Guerci-Bresler AP; Maloisel F; Rea D; Coiteux V; Gardembas M; Berthou C; Vekhoff A; Jourdan E; Berger M; Fouillard L; Alexis M; Legros L; Rousselot P; Delmer A; Lenain P; Escoffre Barbe M; Gyan E; Bulabois CE; Dubruille V; Joly B; Pollet B; Cony-Makhoul P; Johnson-Ansah H; Mercier M; Caillot D; Charbonnier A; Kiladjian JJ; Chapiro J; Penot A; Dorvaux V; Vaida I; Santagostino A; Roy L; Zerazhi H; Deconinck E; Maisonneuve H; Plantier I; Lebon D; Arkam Y; Cambier N; Ghomari K; Miclea JM; Glaisner S; Cayuela JM; Chomel JC; Muller M; Lhermitte L; Delord M; Preudhomme C; Etienne G; Mahon FX; Nicolini FE;
Leukemia; 2021 Aug; 35(8):2332-2345. PubMed ID: 33483613
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy and safety analysis of interferon combined with imatinib in treating chronic myeloid leukemia].
Liu Y; Bao EN; Zhong WW; Lu XC; Zhu HL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Apr; 22(2):304-9. PubMed ID: 24762996
[TBL] [Abstract][Full Text] [Related]
20. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
Kantarjian HM; O'Brien S; Cortes J; Giles FJ; Rios MB; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Verstovsek S; Wierda W; Keating M; Talpaz M
Cancer; 2003 Dec; 98(12):2636-42. PubMed ID: 14669283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
